Results 151 to 160 of about 15,200 (191)

Daratumumab in relapsed or refractory immune thrombocytopenic purpura. [PDF]

Blood Sci
Tomuleasa C, Gale RP.
europepmc   +1 more source

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study [PDF]

, 2019
Ahmadi, T, Arkenau, HT, Boccadoro, M, Cavenagh, J, Chen, D, Chiu, C, de Boer, C, Gay, F, Krejcik, J, Laubach, JP, Minnema, MC, Moreau, P, Perrot, A, Plesner, T, Richardson, PG, Schecter, JM   +15 more
core  

Absence of Red Blood Cell Alloimmunization in Transfused Patients Receiving Daratumumab: Experience from a Single Center. [PDF]

J Clin Med
Eritzpokhoff L, Talegón De La Fuente E, Carril Barcia A, Asensi Cantó P, Gómez Segui I, Arnao Herraiz M, De La Rubia Comos J, Solves Alcaina P.   +7 more
europepmc   +1 more source

Pure Red Cell Aplasia After ABO-Incompatible Allogeneic Hematopoietic Stem Cell Transplantation Successfully Treated With Daratumumab: Report of Two Cases. [PDF]

J Med Cases
Bertone EJ, Milanesio M, de Jesus Garcia M, Castellanos LR, Pirazzini EL, Damonte VA, Basquiera AL.   +6 more
europepmc   +1 more source

Contextualizing results of randomized trials in smoldering myeloma. [PDF]

Oncologist
Mohyuddin GR, Goodman AM, Chakraborty R.
europepmc   +1 more source

Daratumumab-EPOCH for transformed anaplastic multiple myeloma. [PDF]

Hematol Transfus Cell Ther
Stormorken E, Dahm AEA.
europepmc   +1 more source

Cost-per-responder analysis of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone among transplant-eligible patients with newly diagnosed multiple myeloma. [PDF]

J Manag Care Spec Pharm
Gautam S, Morrison L, Thompson-Leduc P, Moore B, Wong G, Macomson B, Khare V, Gupta-Werner N, Medhekar R.   +8 more
europepmc   +1 more source

Emerging Real-World Treatment Patterns and Clinical Outcomes of Multiple Myeloma in Argentina and Brazil: Insights from the TOTEMM Study in the Private Healthcare Sector. [PDF]

Curr Oncol
Hungria V, Maiolino A, Pessoa de Magalhães RJ, Pitombeira de Lacerda M, Remaggi G, Scibona P, Seehaus C, Brulc E, Savoy N, Fantl D, Soares C, Abreu G, Queiroz J, Bernardino G, Tanaka S, Carrizo M, Simonovich VA, Bertoldo Teixeira Fernandes T, Aggarwal B.   +18 more
europepmc   +1 more source